Extracting post-acute sequelae of SARS-CoV-2 infection symptoms from clinical notes via hybrid natural language processing.

Extracting post-acute sequelae of SARS-CoV-2 infection symptoms from clinical notes via hybrid natural language processing.

Publication date: Aug 21, 2025

Accurately and efficiently diagnosing Post-Acute Sequelae of COVID-19 (PASC) remains challenging due to its myriad symptoms that evolve over long- and variable-time intervals. To address this issue, we developed a hybrid natural language processing pipeline that integrates rule-based named entity recognition with BERT-based assertion detection modules for PASC-symptom extraction and assertion detection from clinical notes. We developed a comprehensive PASC lexicon with clinical specialists. From 11 health systems of the RECOVER initiative network across the U. S., we curated 160 intake progress notes for model development and evaluation, and collected 47,654 progress notes for a population-level prevalence study. We achieved an average F1 score of 0. 82 in one-site internal validation and 0. 76 in 10-site external validation for assertion detection. Our pipeline processed each note at 2. 448 +/- 0. 812 seconds on average. Spearman correlation tests showed ρ > 0. 83 for positive mentions and ρ > 0. 72 for negative ones, both with P

Open Access PDF

Concepts Keywords
Challenging Acute
Clinical Assertion
Models Based
Spearman Clinical
Detection
Developed
Hybrid
Natural
Notes
Pasc
Pipeline
Post
Processing
Sequelae
Symptoms

Semantics

Type Source Name
disease MESH post-acute sequelae of SARS-CoV-2 infection
disease IDO entity
disease IDO symptom
disease IDO site
disease MESH sequelae
disease MESH SARS CoV 2 infection
drug DRUGBANK Coenzyme M
pathway REACTOME Reproduction
disease IDO complex infection
disease MESH chronic condition
disease MESH Postural Orthostatic Tachycardia Syndrome
disease MESH syndrome
disease MESH Myalgic Encephalomyelitis
disease IDO history
disease MESH depression
disease MESH anxiety
drug DRUGBANK Alpha-1-proteinase inhibitor
disease IDO process

Original Article

(Visited 8 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *